Table 3.

Univariable hazard ratios for time to first CMV episode by type of episode (CMV infection or CMV disease)

Risk factor		CMV infection1			CMV disease
		N	Hazard ratio (95% CI)	P-value	N	Hazard ratio (95% CI)	P-value
No CMVIG		269	3.3 (1.2, 9.0)	0.022	329	1.01 (0.57, 1.8)	0.97
Donor and recipient		264		0.002	320		0.002
CMV status
	Donor −Recipient−		Reference			Reference
	Donor+Recipient+		12.5 (3.0, 52.7)			5.4 (1.6, 18.2)
	Donor+Recipient−		7.0 (1.6, 29.7)			6.9 (2.1, 22.2)
	Donor−Recipient+		6.3 (1.4, 28.6)			2.4 (0.63, 9.4)
Transplant type		269		0.42	329		0.039
	Heart and lung		Reference			Reference
	Tx type Single		3.8 (0.48, 29.9)			4.5 (1.4, 14.3)
	Tx type Double/Other		1.3 (0.64, 2.7)			1.4 (0.72, 2.7)
Era of transplant		269		0.14	329		0.010
	Year 2003–2005		Reference			Reference
	Year 1992–1994		1.5 (0.73, 3.2)			4.3 (1.8, 10.3)
	Year 1995–1997		0.71 (0.33, 1.5)			2.2 (0.90, 5.5)
	Year 1998–1999		0.54 (0.21, 1.4)			3.4 (1.4, 8.4)
	Year 2000–2003		0.68 (0.33, 1.4)			2.3 (0.97, 5.4)
Female gender		269	1.3 (0.76, 2.2)	0.34	329	1.2 (0.77, 1.9)	0.40
Age at transplant		268		0.88	328		0.11
	Age 0– 7.5 yrs		Reference			Reference
	Age 7.6–12.1 yrs		1.5 (0.66, 3.4)			1.9 (0.79, 4.4)
	Age 12.1–14.3 yrs		1.3 (0.58, 3.0)			2.0 (0.87, 4.7)
	Age 14.3–17.0 yrs		1.4 (0.62, 3.2)			1.6 (0.67, 3.8)
	Age 17.0–21.0 yrs		1.2 (0.47, 2.8)			2.9 (1.3, 6.5)
Cystic Fibrosis etiology		268	1.07 (0.64, 1.8)	0.79	328	1.01 (0.64, 1.6)	0.96
Donor CMV positive		267	2.8 (1.5, 5.2)	0.002	325	3.8 (2.0, 7.5)	<0.001
Recipient CMV positive		266	2.2 (1.3, 3.6)	0.004	324	0.85 (0.53, 1.4)	0.49
Any induction treatment		251	1.2 (0.73, 2.1)	0.43	304	1.2 (0.72, 1.9)	0.53
Immunosuppressive regimen: cyclosporine		269	2.1 (1.09, 3.9)	0.026	329	1.10 (0.68, 1.8)	0.71
A2 rejection prior to CMV		269	1.1 (0.68, 1.9)	0.62	329	1.00 (0.64, 1.6)	0.99
BOS prior to CMV		269	0.20 (0.05, 0.84)	0.027	329	0.19 (0.05, 0.76)	0.019

¹CMV infection, excluding those with CMV disease without prior infection